There is a high heterogeneity in ORR among newly diagnosed IDH-mutated AML patients receiving combination therapy with IDH inhibitors (I2 = 82%), which derives from the different drugs combined with IDH inhibitors (azacitidine: 3 cohorts, intensive chemotherapy: 1 cohort). The gene discussed is IDH1; the disease is acute myeloid leukemia.